Alembic Pharmaceuticals has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tretinoin Cream USP, 0.05%.
The approval marks another addition to Alembic’s growing portfolio in the United States market and strengthens the company’s presence in the dermatology segment.
The approved product is therapeutically equivalent to Retin-A Cream, 0.05%, the reference listed drug (RLD) marketed by Bausch Health US, LLC.
This means Alembic’s Tretinoin Cream can be prescribed as a generic alternative to the branded product while meeting the same quality, safety, and effectiveness standards required by the USFDA.
The approval allows Alembic to market and distribute the product in the United States following all applicable regulatory requirements.
Tretinoin Cream is commonly prescribed for the topical treatment of acne vulgaris, one of the most common skin conditions affecting adolescents and adults.
The medicine works by helping the skin renew itself more quickly, reducing the formation of acne lesions and improving overall skin appearance over time.
Healthcare professionals prescribe tretinoin as part of acne management plans, depending on the severity and type of acne being treated. Patients are advised to refer to the product label and follow medical guidance for detailed usage instructions and indications.
With this latest approval, Alembic Pharmaceuticals continues to expand its footprint in the highly competitive U.S. generics market.
The company has steadily built a broad portfolio of approved products through its regulatory and product development efforts. Receiving final approval for Tretinoin Cream further demonstrates Alembic’s commitment to bringing affordable treatment options to patients.
Following this approval, Alembic Pharmaceuticals now holds a cumulative total of 242 ANDA approvals from the USFDA.
The total includes:
This growing number reflects the company’s continued focus on product development, regulatory compliance, and expansion in key therapeutic categories across the United States pharmaceutical market.
Strengthening Presence in Dermatology Treatments
The approval of Tretinoin Cream USP, 0.05% adds another dermatology product to Alembic’s portfolio. As demand for effective and affordable acne treatments continues, the company is positioned to support healthcare providers and patients with a quality generic alternative.
The latest USFDA approval also highlights Alembic’s ongoing efforts to expand access to essential medicines while strengthening its presence in global pharmaceutical markets.